Accretion Pharma reported robust half-year results (H1 FY26) with revenue jumping 135.59% YoY to ₹43.74 Cr.

Profit after tax (PAT) surged 92.81% YoY to ₹4.75 Cr, while EBITDA grew 62.94% to ₹7.07 Cr.

This strong performance is driven by its integrated CDMO and private-label formulation model, covering oral solids, liquids, and external preparations.

The company's strategy involves geographical diversification, expanding its direct market presence across Asia and Africa.

Key growth drivers include new product development and modernizing its Ahmedabad plant for enhanced efficiency.

Recent developments include IPO-funded capacity upgrades and securing cGMP approval from Malawi, boosting its direct export capabilities in key African markets.

Management remains optimistic, eyeing sustained, compliant growth powered by a diversified customer base and global certifications.